Solid Biosciences to Participate at Upcoming Investor Conferences
Rhea-AI Summary
Solid Biosciences (Nasdaq: SLDB) will participate in two investor conferences in late 2025 with senior management presenting in fireside chats.
- Jefferies Global Healthcare Conference (London) — Bo Cumbo, President and CEO, and Gabriel Brooks, MD, Chief Medical Officer, will speak on Nov 18, 2025 at 11:00 a.m. GMT (6:00 a.m. ET).
- Piper Sandler 37th Annual Healthcare Conference — the same executives will speak on Dec 2, 2025 at 11:30 a.m. ET.
Live webcasts will be available on the company Investors Events page, and replay files will be archived there for 30 days. Institutional investors seeking one-on-one meetings should contact their Jefferies or Piper Sandler representatives.
Positive
- None.
Negative
- None.
News Market Reaction 39 Alerts
On the day this news was published, SLDB gained 9.16%, reflecting a notable positive market reaction. Argus tracked a peak move of +14.5% during that session. Our momentum scanner triggered 39 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $32M to the company's valuation, bringing the market cap to $387M at that time. Trading volume was above average at 1.5x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
CHARLESTOWN, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences:
- Jefferies Global Healthcare Conference in London
Bo Cumbo, President and CEO, and Gabriel Brooks, MD, Chief Medical Officer, will participate in a fireside chat on Tuesday, November 18, 2025, at 11:00 a.m. GMT (6:00 a.m. ET).
- Piper Sandler 37th Annual Healthcare Conference
Mr. Cumbo and Dr. Brooks will participate in a fireside chat on Tuesday, December 2, 2025, at 11:30 a.m. ET.
Live webcasts of the Jefferies and Piper Sandler fireside chats will be available on the Events page of the Investors section of the Company website or by clicking here. Webcast replays will be archived for 30 days on the Events page.
Institutional investors interested in one-on-one meetings with management during the conferences may reach out to their Jefferies or Piper Sandler representatives.
About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including SGT-003 for Duchenne muscular dystrophy (Duchenne), SGT-212 for Friedreich’s ataxia (FA), SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for TNNT2-mediated dilated cardiomyopathy and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com.
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
FAQ
When will Solid Biosciences (SLDB) present at the Jefferies Global Healthcare Conference in 2025?
What time is the Solid Biosciences (SLDB) fireside chat at the Piper Sandler 2025 healthcare conference?
Where can investors watch the Solid Biosciences (SLDB) conference webcasts?
Who from Solid Biosciences (SLDB) will speak at the November–December 2025 conferences?
How long will the Solid Biosciences (SLDB) webcast replays remain available after the events?
How can institutional investors request one-on-one meetings with Solid Biosciences (SLDB) at the conferences?
